Holen Sie sich die Stockscreener-App
25.53
0.20%
0.05
Handel nachbörslich:
25.53
Schlusskurs vom Vortag:
$25.48
Offen:
$25.68
24-Stunden-Volumen:
135.94K
Relative Volume:
0.85
Marktkapitalisierung:
$702.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.47M
KGV:
-4.5611
EPS:
-5.5973
Netto-Cashflow:
$-73.92M
1W Leistung:
+3.99%
1M Leistung:
-11.57%
6M Leistung:
+2.82%
1J Leistung:
+0.00%
1-Tages-Spanne:
$25.30
$27.46
1-Wochen-Bereich:
$23.51
$27.46
52-Wochen-Spanne:
$14.42
$38.93
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Firmenname
Lenz Therapeutics Inc
Sektor
Branche
Telefon
858-925-7000
Adresse
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Vergleichen Sie LENZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
25.53 | 702.10M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-27 | Eingeleitet | Raymond James | Outperform |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-04-10 | Eingeleitet | Citigroup | Buy |
| 2024-03-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-25 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-01-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-14 | Eingeleitet | BTIG Research | Buy |
| 2022-03-22 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-07-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Lenz Therapeutics Inc Aktie (LENZ) Neueste Nachrichten
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 5.1%Time to Sell? - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Trading Up 8%Here's Why - MarketBeat
What is Leerink Partnrs' Estimate for LENZ FY2025 Earnings? - MarketBeat
Leerink Partnrs Has Pessimistic View of LENZ FY2025 Earnings - Defense World
More Heart, Less Skin: US FDA’s 2025 Novel Approvals Should Reflect Pipeline Shifts - News & Insights
Myopia Pipeline 2024: Detailed Clinical Trials - openPR
LENZ Therapeutics (LENZ) Expected to Announce Earnings on Wednesday - Defense World
Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsight - EIN News
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Sees Significant Increase in Short Interest - Defense World
Lincoln Electric Holdings, Inc. (NASDAQ:LECO) Short Interest Down 5.0% in December - Defense World
LifeVantage Co. (NASDAQ:LFVN) Short Interest Down 5.4% in December - Defense World
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Sees Significant Increase in Short Interest - Defense World
Morgan Stanley Cuts U.S. Bancorp (NYSE:USB) Price Target to $59.00 - Defense World
Short Interest in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Expands By 11.9% - MarketBeat
Barclays PLC Has $391,000 Stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Barclays PLC Buys 12,051 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 5%Time to Sell? - MarketBeat
Trio-Tech International (NYSE:TRT) Coverage Initiated by Analysts at StockNews.com - Defense World
Harbor Capital Advisors Inc. Buys Shares of 43,989 LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) PT at $35.40 - Defense World
Jane Street Group LLC Acquires Shares of 12,027 LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 8.9%Here's What Happened - MarketBeat
Intellia stock hurts gene editing after layoffs (NTLA:NASDAQ) - Seeking Alpha
Lenz Therapeutics New Becomes Oversold (LENZ) - Nasdaq
Financial Survey: Fresh Tracks Therapeutics (NASDAQ:FRTX) vs. LENZ Therapeutics (NASDAQ:LENZ) - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Average Rating of "Buy" from Brokerages - MarketBeat
SkyWater Technology, Inc. (NASDAQ:SKYT) Shares Purchased by Barclays PLC - Defense World
NI Holdings, Inc. (NASDAQ:NODK) Shares Purchased by Barclays PLC - Defense World
Barclays PLC Raises Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Geode Capital Management LLC Lowers Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Sold by Geode Capital Management LLC - Defense World
Neumora plummets on depression drug data - BioPharma Dive
Companies Like LENZ Therapeutics (NASDAQ:LENZ) Are In A Position To Invest In Growth - Simply Wall St
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 4.1%What's Next? - MarketBeat
State Street Corp Raises Stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by State Street Corp - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Trading Up 6.3%Should You Buy? - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 4.1% – What’s Next? - Defense World
Wellington Management Group LLP Invests $585,000 in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 4.1%Time to Sell? - MarketBeat
BNP Paribas Financial Markets Has $63,000 Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Presbyopia Therapeutics Market Size was highest in the US among the 7MM, was ~USD 8,039 million, and is expected to increase by 2034 | DelveInsight - Barchart
Presbyopia Therapeutics Market Size was highest in the US among - openPR
LENZ Therapeutics (NASDAQ:LENZ) Stock Price Up 5.8%Here's What Happened - MarketBeat
Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target at $35.40 - Defense World
Charles Schwab Investment Management Inc. Has $2.93 Million Stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
Charles Schwab Investment Management Inc. Has $2.93 Million Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Sotherly Hotels (NASDAQ:SOHOO) Shares Down 5% – Here’s What Happened - Defense World
XOMA (NASDAQ:XOMAP) Trading Down 0.6% – Should You Sell? - Defense World
Onfolio (NASDAQ:ONFO) Trading 1.1% Higher – Should You Buy? - Defense World
Finanzdaten der Lenz Therapeutics Inc-Aktie (LENZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):